Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Gerasimos Konidaris"'
Autor:
Gerasimos Konidaris, Diana Rofail, Jason Randall, Patrick R. LaFontaine, Chieh-I. Chen, Denise Bury, Ashley Geiger, Medha Sasane, Tara Symonds
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 8, Pp 1747-1761 (2023)
Abstract Introduction Evidence of patients’ experiences of living with advanced basal cell carcinoma (aBCC) are limited, particularly after hedgehog pathway inhibitor (HHI) treatment. We explored the burden of aBCC on symptoms and patients’ every
Externí odkaz:
https://doaj.org/article/1e987f0f944244feafbc97352b5c0275
Autor:
Josephine Louella Feliciano, Dylan McLoone, Yingxin Xu, Ruben G.W. Quek, Andreas Kuznik, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel, Patricia Guyot, Gerasimos Konidaris, Keith Chan, Sam Keeping, Florence R. Wilson, Nick Freemantle
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
ObjectivesIn randomized-controlled crossover design trials, overall survival (OS) treatment effect estimates are often confounded by the control group benefiting from treatment received post-progression. We estimated the adjusted OS treatment effect
Externí odkaz:
https://doaj.org/article/c18f66be84a1487fa49aaa999318f8aa
Autor:
Nick Freemantle, Yingxin Xu, Florence R. Wilson, Patricia Guyot, Chieh-I Chen, Sam Keeping, Gerasimos Konidaris, Keith Chan, Andreas Kuznik, Kokuvi Atsou, Emily Glowienka, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemipli
Externí odkaz:
https://doaj.org/article/c77ec0702e844373862097cbebd50839
Autor:
Tim Reynolds, Peter Carey, Jacob George, Gerasimos Konidaris, Deepa Narayanan, Sudarshan Ramachandran, Luke Saunders, Adie Viljoen, Gordon Ferns
Publikováno v:
Drugs - Real World Outcomes, Vol 6, Iss 4, Pp 205-213 (2019)
Abstract Background Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of low-densit
Externí odkaz:
https://doaj.org/article/b5a41f369992465e9ecd7add54203f9c
Autor:
Tamta Makharadze, Ruben G. W. Quek, Tamar Melkadze, Miranda Gogishvili, Cristina Ivanescu, Davit Giorgadze, Mikhail Dvorkin, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Christian Gessner, Brizio Moreno‐Jaime, Rodolfo Passalacqua, Gerasimos Konidaris, Petra Rietschel, Giuseppe Gullo
Publikováno v:
Cancer.
Autor:
Emily Glowienka, Yingxin Xu, Florence Wilson, Patricia Guyot, Sam Keeping, Kokuvi Atsou, Meena Venkatachalam, Caitlin Smare, Chieh-I Chen, Andreas Kuznik, Gerasimos Konidaris, Keith Syson Chan
Publikováno v:
Value in Health. 25:203-214
Objectives This study aimed to evaluate the cost-effectiveness, from a US commercial payer perspective, of cemiplimab versus other first-line treatments for advanced non-small cell lung cancer with programmed death-ligand 1 expression ≥50%. Methods
Autor:
Yingxin Xu, Eleanor Paul, Patricia Guyot, Chieh-I Chen, Andreas Kuznik, Medha Sasane, Sam Keeping, Shannon Cope, Gerasimos Konidaris, Ali Mojebi, Dieter Ayers, Kokuvi Atsou
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 27:1513-1525
BACKGROUND: Most cutaneous squamous cell carcinomas (CSCCs) can be treated with surgical excision or radiation; however, approximately 1% of patients develop advanced disease. In 2018, the FDA appr...
Autor:
Mahmut Gümüş, Chieh‐I Chen, Cristina Ivanescu, Saadettin Kilickap, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Haci M. Turk, Irfan Cicin, James Harnett, Vera Mastey, Ulrike Naumann, Matthew Reaney, Gerasimos Konidaris, Medha Sasane, Keri J. S. Brady, Siyu Li, Giuseppe Gullo, Petra Rietschel, Ahmet Sezer
Publikováno v:
CancerREFERENCES. 129(1)
Background In the EMPOWER-Lung 1 trial (, NCT03088540), cemiplimab conferred longer survival than platinum-doublet chemotherapy for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%. Patient-reported outco
Autor:
Gerasimos Konidaris, Florence Wilson, Meena Venkatachalam, Patricia Guyot, Chieh-I Chen, Andreas Kuznik, Sam Keeping, Emily Glowienka, Keith Syson Chan, Caitlin Smare, Yingxin Xu, Kokuvi Atsou
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:HSR21-057
Autor:
Sudarshan Ramachandran, Gerasimos Konidaris, Gordon A. Ferns, Deepa Narayanan, Jacob George, Luke Saunders, Adie Viljoen, Timothy M Reynolds, Peter Carey
Publikováno v:
Drugs-Real World Outcomes, Vol 6, Iss 4, Pp 205-213 (2019)
Drugs-Real World Outcomes
Drugs-Real World Outcomes
Background Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of low-density lipopro